Stage IV head and neck cutaneous squamous cell carcinoma ajcc V8
Clinical trials for Stage IV head and neck cutaneous squamous cell carcinoma ajcc V8 explained in plain language.
Never miss a new study
Get alerted when new Stage IV head and neck cutaneous squamous cell carcinoma ajcc V8 trials appear
Sign up with your email to follow new studies for Stage IV head and neck cutaneous squamous cell carcinoma ajcc V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control PausedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Weekly chemo may be gentler for head and neck cancer patients
Disease control PausedThis study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase 2/3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC